Literature DB >> 21159660

Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.

Shengnan Zhang1, Violeta Chitu, E Richard Stanley, Bruce E Elliott, Peter A Greer.   

Abstract

Fes is a protein tyrosine kinase with cell autonomous oncogenic activities that are well established in cell culture and animal models, but its involvement in human cancer has been unclear. Abundant expression of Fes in vascular endothelial cells and myeloid cell lineages prompted us to explore roles for Fes in the tumor microenvironment. In an orthotopic mouse model of breast cancer, we found that loss of Fes in the host correlated with reductions in engrafted tumor growth rates, metastasis, and circulating tumor cells. The tumor microenvironment in Fes-deficient mice also showed reduced vascularity and fewer macrophages. In co-culture with tumor cells, Fes-deficient macrophages also poorly promoted tumor cell invasive behavior. Taken together, our observations argue that Fes inhibition might provide therapeutic benefits in breast cancer, in part by attenuating tumor-associated angiogenesis and the metastasis-promoting functions of tumor-associated macrophages. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159660      PMCID: PMC3041852          DOI: 10.1158/0008-5472.CAN-10-3757

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Activated Fes protein tyrosine kinase induces terminal macrophage differentiation of myeloid progenitors (U937 cells) and activation of the transcription factor PU.1.

Authors:  Jynho Kim; Ricardo A Feldman
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

Review 2.  Closing in on the biological functions of Fps/Fes and Fer.

Authors:  Peter Greer
Journal:  Nat Rev Mol Cell Biol       Date:  2002-04       Impact factor: 94.444

3.  Fes tyrosine kinase promotes survival and terminal granulocyte differentiation of factor-dependent myeloid progenitors (32D) and activates lineage-specific transcription factors.

Authors:  Jynho Kim; Yoshiyasu Ogata; Ricardo A Feldman
Journal:  J Biol Chem       Date:  2003-02-12       Impact factor: 5.157

4.  Mutational analysis of the tyrosine kinome in colorectal cancers.

Authors:  Alberto Bardelli; D Williams Parsons; Natalie Silliman; Janine Ptak; Steve Szabo; Saurabh Saha; Sanford Markowitz; James K V Willson; Giovanni Parmigiani; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2003-05-09       Impact factor: 47.728

5.  Enhanced endotoxin sensitivity in fps/fes-null mice with minimal defects in hematopoietic homeostasis.

Authors:  Ralph A Zirngibl; Yotis Senis; Peter A Greer
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

6.  Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.

Authors:  Seyedhossein Aharinejad; Dietmar Abraham; Patrick Paulus; Hojatollah Abri; Michael Hofmann; Karl Grossschmidt; Romana Schäfer; E Richard Stanley; Reinhold Hofbauer
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

Review 7.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor.

Authors:  Antonia Patsialou; Jeffrey Wyckoff; Yarong Wang; Sumanta Goswami; E Richard Stanley; John S Condeelis
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

9.  Fer kinase is required for sustained p38 kinase activation and maximal chemotaxis of activated mast cells.

Authors:  Andrew W B Craig; Peter A Greer
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.

Authors:  E Y Lin; A V Nguyen; R G Russell; J W Pollard
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  11 in total

1.  Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.

Authors:  Lauren S Fink; Alexander Beatty; Karthik Devarajan; Suraj Peri; Jeffrey R Peterson
Journal:  Mol Cancer Ther       Date:  2014-10-24       Impact factor: 6.261

2.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.

Authors:  Natalie H Theodoulou; Paul Bamborough; Andrew J Bannister; Isabelle Becher; Rino A Bit; Ka Hing Che; Chun-wa Chung; Antje Dittmann; Gerard Drewes; David H Drewry; Laurie Gordon; Paola Grandi; Melanie Leveridge; Matthew Lindon; Anne-Marie Michon; Judit Molnar; Samuel C Robson; Nicholas C O Tomkinson; Tony Kouzarides; Rab K Prinjha; Philip G Humphreys
Journal:  J Med Chem       Date:  2015-04-30       Impact factor: 7.446

3.  Integrative multi-omic analysis identifies genetically influenced DNA methylation biomarkers for breast and prostate cancers.

Authors:  Anita Sathyanarayanan; Hamzeh M Tanha; Divya Mehta; Dale R Nyholt
Journal:  Commun Biol       Date:  2022-06-16

4.  Targeting the tumor microenvironment: focus on angiogenesis.

Authors:  Fengjuan Fan; Alexander Schimming; Dirk Jaeger; Klaus Podar
Journal:  J Oncol       Date:  2011-08-24       Impact factor: 4.375

5.  The BAR Domain Superfamily Proteins from Subcellular Structures to Human Diseases.

Authors:  Fatemeh Safari; Shiro Suetsugu
Journal:  Membranes (Basel)       Date:  2012-02-27

6.  SPE-8, a protein-tyrosine kinase, localizes to the spermatid cell membrane through interaction with other members of the SPE-8 group spermatid activation signaling pathway in C. elegans.

Authors:  Paul J Muhlrad; Jessica N Clark; Ubaydah Nasri; Nicholas G Sullivan; Craig W LaMunyon
Journal:  BMC Genet       Date:  2014-07-14       Impact factor: 2.797

7.  Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.

Authors:  Akihiro Asai; Yasuyoshi Miyata; Kosuke Takehara; Shigeru Kanda; Shin-Ichi Watanabe; Peter A Greer; Hideki Sakai
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-26       Impact factor: 4.553

8.  Comprehensive analysis of the genome transcriptome and proteome landscapes of three tumor cell lines.

Authors:  Pelin Akan; Andrey Alexeyenko; Paul Igor Costea; Lilia Hedberg; Beata Werne Solnestam; Sverker Lundin; Jimmie Hällman; Emma Lundberg; Mathias Uhlén; Joakim Lundeberg
Journal:  Genome Med       Date:  2012-11-18       Impact factor: 11.117

9.  Interleukin-4 Expressed By Neoplastic Cells Provokes an Anti-Metastatic Myeloid Immune Response.

Authors:  Connie S Zhang; Hyeyeon Kim; Graeme Mullins; Kathrin Tyryshkin; David P LeBrun; Bruce E Elliott; Peter A Greer
Journal:  J Clin Cell Immunol       Date:  2015-05-31

10.  Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent.

Authors:  Michael Behring; Yuanfan Ye; Amr Elkholy; Prachi Bajpai; Sumit Agarwal; Hyung-Gyoon Kim; Akinyemi I Ojesina; Howard W Wiener; Upender Manne; Sadeep Shrestha; Ana I Vazquez
Journal:  Cancer Med       Date:  2021-06-29       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.